Presentation of Vitrolife for the benefit of MediCult's shareholders

Presentation of Vitrolife for the benefit of MediCult's shareholders

Vitrolife AB (publ) (“Vitrolife”) invites the shareholders of MediCult a/s
(“MediCult”) (OSE: MEC) to attend a presentation by Vitrolife's CEO, Magnus
Nilsson. 

On Wednesday 28 January 2009 at 12.00 CET, Mr. Nilsson will give a presentation
of Vitrolife and its products for the benefit of the shareholders of MediCult.
In addition, Mr. Nilsson will give his views on the proposed combination of
Vitrolife and MediCult. Refreshments will be served.


Location:
Carnegie Conference Centre, Stranden 1B, 3.etg, Oslo.


Please email ah@carnegie.no if you are interested in attending the presentation.













Queries should be addressed to: 
Anita Ahlqvist, CEO Assistant, phone +46 31 721 80 83


________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 150 employees and the company's products
are sold in more than 80 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France and Italy.
Production facilities are housed in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.